Abstract:Positive PDL1 expression was observed in NF2‐meningiomas, downregulation of PD‐L1 could inhibit tumor cell proliferation, promote apoptosis, and suppress the inhibitory effect of tumor cells on T‐cell activation and cytotoxicity. NF2 may regulate PD‐L1 expression through the PI3K–AKT–mTOR pathway, anti‐PD‐L1 antibody may have a synergetic effect with the mTOR inhibitor in reducing tumor cell proliferation. Introduction Programmed death‐ligand 1 (PD‐L1) expression is an immune evasion mechanism that has been demonstrated in many tumors and is commonly associated with a poor prognosis. Over the years, anti‐PD‐L1 agents have gained attention as novel anticancer therapeutics that induce durable tumor regression in numerous malignancies. They may be a new treatment choice for neurofibromatosis type 2 (NF2) patients. Aims The aims of this study were to detect the expression of PD‐L1 in NF2‐associated meningiomas, explore the effect of PD‐L1 downregulation on tumor cell characteristics and T‐cell functions, and investigate the possible pathways that regulate PD‐L1 expression to further dissect the possible mechanism of immune suppression in NF2 tumors and to provide new treatment options for NF2 patients. Results PD‐L1 is heterogeneously expressed in NF2‐associated meningiomas. After PD‐L1 knockdown in NF2‐associated meningioma cells, tumor cell proliferation was significantly inhibited, and the apoptosis rate was elevated. When T cells were cocultured with siPD‐L1‐transfected NF2‐associated meningioma cells, the expression of CD69 on both CD4+ and CD8+ T cells was partly reversed, and the capacity of CD8+ T cells to kill siPD‐L1‐transfected tumor cells was partly restored. Results also showed that the PI3K–AKT–mTOR pathway regulates PD‐L1 expression, and the mTOR inhibitor rapamycin rapidly and persistently suppresses PD‐L1 expression. In vivo experimental results suggested that anti‐PD‐L1 antibody may have a synergetic effect with the mTOR inhibitor in reducing tumor cell proliferation and that reduced PD‐L1 expression could contribute to antitumor efficacy. Conclusions Targeting PD‐L1 could be helpful for restoring the function of tumor‐infiltrating lymphocytes and inducing apoptosis to inhibit tumor proliferation in NF2‐associated meningiomas. Dissecting the mechanisms of the PD‐L1‐driven tumorigenesis of NF2‐associated meningioma will help to improve our understanding of the mechanisms underlying tumor progression and could facilitate further refinement of current therapies to improve the treatment of NF2 patients.

Blocking PD1/PDL1 Interactions Together with MLN4924 Therapy is a Potential Strategy for Glioma Treatment

Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo

Targeted Regulation of Blood-Brain Barrier for Enhanced Therapeutic Efficiency of Hypoxia-Modifier Nanoparticles and Immune Checkpoint Blockade Antibodies for Glioblastoma

Suppression of Glioblastoma by Targeting the Overactivated Protein Neddylation Pathway.

PD-L1 Inhibitor Regulates the miR-33a-5p/PTEN Signaling Pathway and Can Be Targeted to Sensitize Glioblastomas to Radiation

PD-L1 Induction Via the MEK-JNK-AP1 Axis by a Neddylation Inhibitor Promotes Cancer-Associated Immunosuppression

PD‐L1 regulates tumor proliferation and T‐cell function in NF2‐associated meningiomas

Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation

The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes

Biodegradable Polymeric Nanoparticles Containing an Immune Checkpoint Inhibitor (aPDL1) to Locally Induce Immune Responses in the Central Nervous System

Correction To: Synergism Between the Phosphatidylinositol 3-Kinase P110β Isoform Inhibitor AZD6482 and the Mixed Lineage Kinase 3 Inhibitor URMC-099 on the Blockade of Glioblastoma Cell Motility and Focal Adhesion Formation

The IFN-γ/PD-L1 Axis Between T Cells and Tumor Microenvironment: Hints for Glioma Anti-Pd-1/pd-l1 Therapy.

PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38 MAPK signalling

Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade

Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics

AB042. Combined Anti-Pd-l1 and Anti-Vegfr2 Therapy Promotes the Antitumor Immune Response in Glioblastoma Multiforme by Reprogramming Tumor Microenvironment

1241 Sustained Localized Delivery of Anti-PD-1 to Tumor Draining Lymph Nodes Increases Survival and Reverses Immunosuppression in Murine Glioblastoma Models

PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies

Dddr-39. Pi3 Kinase And Checkpoint Inhibition: A Potentially Novel Therapeutic Strategy For Glioblastoma (Gbm)

PD-1/PD-L1 Blockade Rescue Exhausted CD8+T Cells in Gastrointestinal Stromal Tumours Via the PI3K/Akt/mTOR Signalling Pathway

The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia